Related Experiment Videos
3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists
T M Willson1, B R Henke, T M Momtahen
1Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, USA. willsontm@glaxo.com
Journal of Medicinal Chemistry
|July 19, 1996
Summary
Researchers developed a novel, orally active benzodiazepine that selectively targets the cholecystokinin-A (CCK-A) receptor. This compound demonstrated significant agonist activity in vitro and in vivo, offering a new therapeutic avenue.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- The cholecystokinin-A (CCK-A) receptor plays a crucial role in various physiological processes, including gallbladder contraction and satiety.
- Developing selective agonists for the CCK-A receptor is of therapeutic interest for conditions related to gastrointestinal function and appetite regulation.
Purpose of the Study:
- To synthesize and characterize novel 1,5-benzodiazepine derivatives as CCK-A receptor agonists.
- To evaluate the binding selectivity and in vitro/in vivo activity of modified benzodiazepine compounds.
Main Methods:
- Chemical synthesis of modified 1,5-benzodiazepine structures, focusing on alterations at the C-3 substituent.
- In vitro assessment of CCK-A receptor binding affinity and agonist activity.
- In vivo evaluation using a mouse gallbladder emptying assay.
Main Results:
- Acetamide 6, a modified benzodiazepine, was synthesized with a C-3 quaternary carbon.
- Compound 6 exhibited CCK-A receptor binding selectivity and sub-micromolar agonist activity in vitro.
- Benzodiazepine 6 demonstrated efficacy in an in vivo mouse gallbladder emptying assay.
Conclusions:
- The synthesized acetamide derivative 6 represents a novel, orally active, and binding-selective CCK-A agonist.
- These findings highlight the potential of modified benzodiazepines as therapeutic agents targeting the CCK-A receptor.